Prima BioMed Ltd. (NASDAQ:PBMD)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a research note issued on Tuesday. They presently have a $5.00 price objective on the stock.

Several other equities analysts also recently issued reports on the company. FBR & Co set a $6.00 price objective on Prima BioMed and gave the company a “buy” rating in a research report on Thursday, September 8th. Roth Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Prima BioMed in a research report on Friday, August 26th. Finally, Zacks Investment Research downgraded Prima BioMed from a “buy” rating to a “hold” rating in a research report on Wednesday, August 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $4.20.

Prima BioMed (NASDAQ:PBMD) opened at 0.8151 on Tuesday. The firm has a 50-day moving average of $0.00 and a 200 day moving average of $0.00.

About Prima BioMed

Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.

5 Day Chart for NASDAQ:PBMD

Receive News & Stock Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related stocks with our FREE daily email newsletter.